February 10, 2022 13:30
SK Bioscience on Wednesday produced the first batch of Novavax's antigen-based COVID vaccine.
Nuvaxovid is being made in Andong, North Gyeongsang Province, and SK Bioscience has promised to supply about 2 million doses by the end of this month.
Nuvaxovid was developed from cell cultures of coronavirus spike proteins by the U.S. biotech firm. SK Bioscience secured its manufacturing and supply rights in Korea.
SK Bioscience said its safety and efficacy are assured since synthetic antigen-based vaccines have long been used to prevent flu, hepatitis B and cervical cancer.
Last year, the vaccine proved 90.4 percent effective in preventing COVID in phase-3 clinical trials in the U.S. and Mexico.
Nuvaxovid can be kept in an ordinary fridge at 2 to 8 degrees Celsius, unlike Pfizer's mRNA vaccine which has to be kept at -20 to -70 degrees.
- Copyright © Chosunilbo & Chosun.com